Perioperative Radiation for Patients with Resectable Pancreatic Cancer: an Updated Review After the Initial RTOG 0848 Results

被引:0
作者
Kersch, Cymon N. [1 ]
Grossberg, Aaron J. [1 ,2 ,3 ,4 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Brenden Colson Ctr Pancreat Care, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Canc Early Detect Adv Res Ctr, Portland, OR 97239 USA
[4] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA
关键词
Pancreatic cancer; CRT; RTOG; 0848; ADJUVANT COMBINED RADIATION; CURATIVE RESECTION; DUCTAL ADENOCARCINOMA; RECURRENCE PATTERNS; CHEMOTHERAPY; GEMCITABINE; SURVIVAL; CHEMORADIATION; THERAPY; PANCREATICODUODENECTOMY;
D O I
10.1007/s12029-025-01185-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposePancreatic cancer remains one of the most lethal malignancies, with limited long-term survival despite advances in treatment strategies. While surgical resection offers the best chance for cure in localized disease, high rates of recurrence underscore the need for effective adjuvant therapies. Over four decades, the role of adjuvant chemoradiation (CRT) has been the subject of significant debate, with numerous trials yielding mixed outcomes regarding its impact on survival. Improvements in chemotherapy regimens and radiotherapy techniques have prompted renewed efforts to define the value of CRT, particularly in comparison to chemotherapy alone. The recent initial results of RTOG 0848 mark a critical milestone in this ongoing discussion, providing contemporary evidence that challenges established assumptions and refines patient selection criteria. By identifying specific subgroups-such as lymph node-negative patients-which may benefit from CRT, the trial offers clarity while highlighting the limitations of CRT in other populations.MethodsHerein, we review prior prospective and retrospective trials that investigated the role of perioperative CRT, in particular radiation therapy, for resectable pancreatic cancer.ResultsThis review examines the trajectory of research on CRT in pancreatic cancer, assesses the implications of RTOG 0848 for current clinical practice, and underscores the importance of further studies to optimize the integration of multimodal therapy in the management of this aggressive disease.ConclusionThe combination of results from RTOG 0848 in conjunction with the results of prior prospective and retrospective trials lend support for the use of adjuvant RT for patients with both lymph node-negative and lymph node-positive disease. However, several open questions remain about the role of this therapy in select patient cohorts, and whether neoadjuvant versus advent radiation is optimal.
引用
收藏
页数:18
相关论文
共 69 条
[1]   Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial [J].
Abrams, Ross A. ;
Winter, Kathryn A. ;
Safran, Howard ;
Goodman, Karyn A. ;
Regine, William F. ;
Berger, Adam C. ;
Gillin, Michael T. ;
Philip, Philip A. ;
Lowy, Andrew M. ;
Wu, Abraham ;
DiPetrillo, Thomas A. ;
Corn, Benjamin W. ;
Seaward, Samantha A. ;
Haddock, Michael G. ;
Song, Suisui ;
Jiang, Yixing ;
Fisher, Barbara J. ;
Katz, Alan W. ;
Mehta, Sharmila ;
Willett, Christopher G. ;
Crane, Christopher H. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (03) :173-179
[2]   FAILURE TO ADHERE TO PROTOCOL SPECIFIED RADIATION THERAPY GUIDELINES WAS ASSOCIATED WITH DECREASED SURVIVAL IN RTOG 9704-A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR PATIENTS WITH RESECTED ADENOCARCINOMA OF THE PANCREAS [J].
Abrams, Ross A. ;
Winter, Kathryn A. ;
Regine, William F. ;
Safran, Howard ;
Hoffman, John P. ;
Lustig, Robert ;
Konski, Andre A. ;
Benson, Al B. ;
Macdonald, John S. ;
Rich, Tyvin A. ;
Willett, Christopher G. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :809-816
[3]   Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients [J].
Brunner, Maximilian ;
Flessa, Marteen ;
Jacobsen, Anne ;
Merkel, Susanne ;
Krautz, Christian ;
Weber, Georg F. ;
Gruetzmann, Robert .
PANCREATOLOGY, 2024, 24 (06) :930-937
[4]   Adjuvant therapy for pancreatic cancer - The debate continues [J].
Choti, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1249-1251
[5]   FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].
Conroy, T. ;
Hammel, P. ;
Hebbar, M. ;
Ben Abdelghani, M. ;
Wei, A. C. ;
Raoul, J. -L. ;
Chone, L. ;
Francois, E. ;
Artru, P. ;
Biagi, J. J. ;
Lecomte, T. ;
Assenat, E. ;
Faroux, R. ;
Ychou, M. ;
Volet, J. ;
Sauvanet, A. ;
Breysacher, G. ;
Di Fiore, F. ;
Cripps, C. ;
Kavan, P. ;
Texereau, P. ;
Bouhier-Leporrier, K. ;
Khemissa-Akouz, F. ;
Legoux, J. -L. ;
Juzyna, B. ;
Gourgou, S. ;
O'Callaghan, C. J. ;
Jouffroy-Zeller, C. ;
Rat, P. ;
Malka, D. ;
Castan, F. ;
Bachet, J. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406
[6]   Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer A Randomized Clinical Trial [J].
Conroy, Thierry ;
Castan, Florence ;
Lopez, Anthony ;
Turpin, Anthony ;
Ben Abdelghani, Meher ;
Wei, Alice C. ;
Mitry, Emmanuel ;
Biagi, James J. ;
Evesque, Ludovic ;
Artru, Pascal ;
Lecomte, Thierry ;
Assenat, Eric ;
Bauguion, Lucile ;
Ychou, Marc ;
Bouche, Olivier ;
Monard, Laure ;
Lambert, Aurelien ;
Hammel, Pascal .
JAMA ONCOLOGY, 2022, 8 (11) :1571-1578
[7]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[8]   Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005) [J].
Corsini, Michele M. ;
Miller, Robert C. ;
Haddock, Michael G. ;
Donohue, John H. ;
Farnell, Michael B. ;
Nagorney, David M. ;
Jatoi, Aminah ;
McWilliams, Robert R. ;
Kim, George P. ;
Bhatia, Sumita ;
Iott, Matthew J. ;
Gunderson, Leonard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3511-3516
[9]   Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications [J].
Deig, Christopher Ryan ;
Sutton, Thomas Lee ;
Beneville, Blake ;
Trone, Kristin ;
Stratton, Amanda ;
Gunesch, Ali N. ;
Liu, Amy Ivy ;
Alrohaibani, Alaaeddin ;
Mohebnasab, Maedeh ;
Bassale, Solange ;
Grossblatt-Wait, Alison ;
Keith, Dove ;
Attia, Fouad ;
Gilbert, Erin W. ;
Lopez, Charles D. ;
Kardosh, Adel ;
Chen, Emerson Y. ;
Bensch, Kenneth G. ;
Nabavizadeh, Nima ;
Thomas, Charles R. ;
Mayo, Skye C. ;
Sheppard, Brett C. ;
Grossberg, Aaron .
CANCERS, 2022, 14 (03)
[10]  
DOUGLASS HO, 1987, CANCER-AM CANCER SOC, V59, P2006